Course Provider
Learning Objectives
Upon completion of this activity, participants should be better able to assess real-world data to identify barriers to CAR T-cell therapy integration in earlier lines of R/R MM treatment among hematology/oncology providers
Upon completion of this activity, participants should be better able to evaluate the latest clinical safety and efficacy data for CAR T-cell therapy in R/R MM based on indication, disease characteristics, and patient factors
Upon completion of this activity, participants should be better able to apply evidence-based strategies to guide the selection and sequencing of CAR T-cells for eligible patients with R/R MM
Upon completion of this activity, participants should be better able to employ evidence-based approaches for prompt recognition and multidisciplinary management of CAR T-cell-related adverse events
Upon completion of this activity, participants should be better able to design interprofessional strategies to support coordinated care for CAR T-cell therapy referral, administration, and follow-up for appropriate patients with R/R MM to optimize outcomes